Influenza virus-IN-6 (Compound 35) (7.5-30 mg/kg/d; i.p.; twice daily for 7 days) markedly protects mice from influenza virus infection[1].
Pharmacokinetic (PK) Profile In Vivo of Influenza virus-IN-6 (Compound 35) after a Single Dose in Rats In Vivo (n = 5)a[1]
| parameter | IV (2 mg/kg) | PO (10 mg/kg) | IP (15 mg/kg) |
| T1/2 (h) | 0.33 ± 0.07 | 0.82 ± 0.16 | 1.07 ± 0.25 |
| Tmax (h) | NA | 0.52 | 0.45 |
| Cmax (ng/mL) | 1586.55 ± 366.48 | 92.20 ± 36.25 | 889.52 ± 233.17 |
| AUC0-t (h·ng/mL) | 536.45 ± 58.72 | 164.30 ± 26.37 | 790.62 ± 188.31 |
| CL (mL/min/kg) | 53.76 ± 13.18 | NA | NA |
| F % | NA | 6.13% | 29.50% |
aIV represents intravenous injection, IP represents intraperitoneal injection, and PO represents the gastrointestinal route. T
1/2 is the half-life of the compound exposure in plasma. T
max is the time taken to reach the maximum concentration. C
max represents the highest observed concentration. AUC
(0–t) is the area under the curve. CL (mL/min/kg) is the clearance. F % is the percent bioavailability.
| Animal Model: | Balb/C mice, H1N1 infection model[1] |
| Dosage: | 0, 7.5, 15, and 30 mg/kg/d |
| Administration: | Intraperitoneal injection, twice per day for 7 days |
| Result: | Exhibited excellent anti-IAV activity in vivo at a dose of 30 mg/kg/d. Still showed potent antiviral activity in vivo, with a survival ratio of approximately 60% against lethal virus infection in mice at 15 mg/kg/d.
|
| Animal Model: | SD rats[1] |
| Dosage: | 2, 10 or 15 mg/kg |
| Administration: | IV, IP, or PO (Pharmacokinetic Analysis) |
| Result: | Showed good pharmacokinetic profiles. |
